Tune in on March 17, 2016 from 9-11PM Eastern (267)521-0167 to hear and comment on the Final Draft of Official Complaint to Ombuds Office at FDA concerning the processes that FDA has taken in the proposed down-classification of the shock device

The rule proposed is that for people who are 18 years of age and older, who experience a “depressive episode” as part of “major depressive disorder” or “bipolar disorder” and are “treatment-resistant” or “require rapid response” that the “probable benefit of ECT outweighs these risks” (p. 81228).

March 28, 2016 is deadline for FDA comments.

Tune in to hear the current situation, share your experiences of shock treatment, and encourage others to respond to the FDA.